Dynavax Technologies Past Earnings Performance
Past criteria checks 0/6
Dynavax Technologies has been growing earnings at an average annual rate of 62.1%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 50.5% per year.
Key information
62.1%
Earnings growth rate
66.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 50.5% |
Return on equity | -1.0% |
Net Margin | -2.8% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts
Aug 10Dynavax: Earnings This Year Ought To Surprise To The Upside
Aug 01Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
May 30Dynavax shares down 6% on launch of $200M debt offering
May 10Revenue & Expenses BreakdownBeta
How Dynavax Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 232 | -6 | 160 | 0 |
30 Sep 23 | 361 | 61 | 149 | 5 |
30 Jun 23 | 459 | 111 | 143 | 0 |
31 Mar 23 | 656 | 236 | 142 | 0 |
31 Dec 22 | 723 | 293 | 126 | 0 |
30 Sep 22 | 733 | 320 | 124 | 29 |
30 Jun 22 | 674 | 228 | 119 | 0 |
31 Mar 22 | 470 | 104 | 104 | 0 |
31 Dec 21 | 439 | 72 | 92 | 0 |
30 Sep 21 | 258 | -39 | 81 | 0 |
30 Jun 21 | 163 | -6 | 76 | 0 |
31 Mar 21 | 113 | -62 | 73 | 0 |
31 Dec 20 | 40 | -75 | 72 | 0 |
30 Sep 20 | 38 | -97 | 74 | 0 |
30 Jun 20 | 35 | -138 | 72 | 0 |
31 Mar 20 | 40 | -129 | 73 | 0 |
31 Dec 19 | 35 | -156 | 72 | 0 |
30 Sep 19 | 30 | -159 | 70 | 0 |
30 Jun 19 | 21 | -163 | 68 | 0 |
31 Mar 19 | 14 | -160 | 64 | 0 |
31 Dec 18 | 8 | -159 | 65 | 0 |
30 Sep 18 | 3 | -146 | 58 | 0 |
30 Jun 18 | 1 | -128 | 48 | 0 |
31 Mar 18 | 0 | -109 | 40 | 0 |
31 Dec 17 | 0 | -95 | 27 | 0 |
30 Sep 17 | 8 | -89 | 26 | 0 |
30 Jun 17 | 8 | -102 | 32 | 0 |
31 Mar 17 | 10 | -111 | 36 | 0 |
31 Dec 16 | 11 | -112 | 37 | 0 |
30 Sep 16 | 4 | -118 | 36 | 0 |
30 Jun 16 | 5 | -113 | 30 | 0 |
31 Mar 16 | 4 | -108 | 25 | 0 |
31 Dec 15 | 4 | -107 | 22 | 0 |
30 Sep 15 | 6 | -102 | 21 | 0 |
30 Jun 15 | 7 | -102 | 19 | 0 |
31 Mar 15 | 8 | -103 | 18 | 0 |
31 Dec 14 | 11 | -91 | 18 | 0 |
30 Sep 14 | 12 | -90 | 24 | 0 |
30 Jun 14 | 12 | -76 | 24 | 0 |
31 Mar 14 | 13 | -68 | 22 | 0 |
31 Dec 13 | 11 | -75 | 27 | 0 |
30 Sep 13 | 10 | -74 | 25 | 0 |
30 Jun 13 | 10 | -76 | 27 | 0 |
Quality Earnings: DVAX is currently unprofitable.
Growing Profit Margin: DVAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DVAX is unprofitable, but has reduced losses over the past 5 years at a rate of 62.1% per year.
Accelerating Growth: Unable to compare DVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: DVAX has a negative Return on Equity (-1.03%), as it is currently unprofitable.